{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-063707","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2024-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.232440+00:00","generated_at":"2026-06-01T09:11:39.664353+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Viking Therapeutics stockholders approve 2024 equity plans and re-elect directors at annual meeting","bullets":["Stockholders re-elected Brian Lian (50.5M for, 17.4M withheld) and Lawson Macartney (22.3M for, 45.7M withheld) as Class III directors.","2024 Equity Incentive Plan approved (48.5M for, 19.3M against).","2024 Employee Stock Purchase Plan approved (67.1M for, 0.7M against).","Advisory say-on-pay approved (63.2M for, 4.5M against).","Ratification of Marcum LLP as auditor for FY2024 approved (87.4M for, 0.7M against)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-063707","json":"https://secwatch.observer/filing/0000950170-24-063707.json","markdown":"https://secwatch.observer/filing/0000950170-24-063707.md","text":"https://secwatch.observer/filing/0000950170-24-063707.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000095017024063707/0000950170-24-063707-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000095017024063707/vktx-20240521.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:11:39.664353+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}